SCHEMBL3396098

SCHEMBL3396098

CC(=O)OCc1cc(C)c2ccccc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
MAPT P10636 2/20 0.48
KMT2A Q03164 1/20 0.48
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP2C9 P11712 1/20 0.46
TOP2A P11388 1/20 0.46
TOP2B Q02880 1/20 0.46
BACE1 P56817 1/20 0.45
PRNP P04156 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
CYSLTR1 Q9Y271 1/20 0.44
KDM4E B2RXH2 2/20 0.43
POLB P06746 2/20 0.43
GLA P06280 1/20 0.43
HPGD P15428 1/20 0.43
ALOX12 P18054 1/20 0.43
NPC1 O15118 1/20 0.43
TSHR P16473 1/20 0.43
AKR1C3 P42330 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7967311 0.80 CYP1A2 (0.55) ALDH1A1MAPTKMT2ACYP1A2BACE1
SCHEMBL7967305 0.78 CYP1A2 (0.53) ALDH1A1MAPTKMT2ACYP1A2BACE1
SCHEMBL10764026 0.78 CYP1A2 (0.46) ALDH1A1MAPTKMT2ACYP1A2CYP2C19
SCHEMBL28585633 0.77 CYSLTR1 (0.57) ALDH1A1KMT2ACYP1A2BACE1CYSLTR1
SCHEMBL526457 0.76 CYP1A2 (0.58) ALDH1A1MAPTKMT2ACYP1A2CYP2C19
SCHEMBL25523802 0.76 KDM4E (0.50) ALDH1A1MAPTKMT2ACYP1A2BACE1
SCHEMBL6535305 0.76 KDM4E (0.52) ALDH1A1MAPTKMT2ACYP1A2CYP2C19
SCHEMBL31434350 0.76 NPFFR1 (0.55) ALDH1A1MAPTKMT2ACYP1A2CYP2C19
SCHEMBL3951224 0.75 GPBAR1 (0.55) MAPTKMT2ACYP1A2CYP2C19CYSLTR1
SCHEMBL31130638 0.74 MAPT (0.61) MAPTKMT2ACYP1A2CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2145888-A1 Deazapurine derivatives as HSP90-Inhibitors Conforma Therapeutics Corporation (US) 2010-01-20 EP disclosed
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity CONFORMA THERAPEUTICS CORPORATION (US) 2007-08-09 US disclosed
US-7138401-B2 2-aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION (US) 2006-11-21 US disclosed
EP-1670802-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS Conforma Therapeutic Corporation (US) 2006-06-21 EP disclosed
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION 2005-05-26 US disclosed
WO-2005028434-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS CONFORMA THERAPEUTICS CORPORATION (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity HSP90AB2P, HSP90AB1, HSP90AA1 ALDH1A1 827/4885MAPT 2030/4885KMT2A 2392/4885
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity HSP90AB2P, HSP90AB1, HSP90AA1 ALDH1A1 827/4885MAPT 2030/4885KMT2A 2392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.